GSK's core business model is strongly anchored in specialty medicines with robust growth drivers in HIV, oncology, and respiratory segments, supported by a deep late-stage pipeline and recent FDA approvals. The company’s products and IP are defensible due to regulatory protections and clinical diff…
GSK (GSK) Q2 2025: Specialty Medicines Drive 15% Sales Growth, Boosting Confidence in Long-Term Targets
GSK’s Q2 2025 results highlight robust specialty medicines momentum, underpinning upward revisions in 2025 guidance. Strong R&D progress and disciplined capital allocation reinforce confidence in achieving over £40 billion sales by 2031, despite tariff and supply chain headwinds.
Summary
- Specialty-Led Growth: Double-digit sales expansion in specialty medicines fuels overall top-line momentum.
- R&D Acceleration: Pipeline advances with multiple late-stage assets and new pivotal trials signal sustained innovation.
- Operational Discipline: Margin expansion driven by SG&A efficiency and royalties offsets supply chain and tariff pressures.
Business Overview
GSK is a global biopharmaceutical company focused on developing and commercializing specialty medicines, vaccines, and general medicines. Revenue is primarily generated through its Specialty Medicines segment, which includes HIV, respiratory, immunology, and oncology treatments, alongside a broad vaccines portfolio and a declining general medicines business. Specialty Medicines currently account for approximately 40 percent of sales and are expected to exceed 50 percent by 2031.
Performance Analysis
In Q2 2025, GSK delivered a 6 percent constant exchange rate (CER) increase in total sales to £8.0 billion, driven predominantly by a 15 percent CER rise in Specialty Medicines. This segment’s growth was broad-based, with HIV sales up 12 percent, respiratory, immunology & inflammation (RINI) up 10 percent, and oncology surging 42 percent. Vaccines also contributed with a 9 percent sales increase, led by strong meningitis and shingles vaccine demand in Europe and international markets.
Despite a 6 percent CER sales decline in General Medicines, the overall operating profit expanded robustly, with core operating profit up 12 percent and core earnings per share growing 15 percent. The margin improvement reflects disciplined selling, general and administrative (SG&A) expense management, which declined 1 percent, and a 70 percent boost in royalty income stemming from an intellectual property settlement. However, gross margin faced pressure from supply chain optimization costs and anticipated tariffs, partially offset by favorable product mix from specialty growth.
- HIV Portfolio Expansion: Long-acting injectables like Cabenuva and Apretude drove over 70 percent of HIV growth, with Cabenuva sales up 46 percent and Apretude up 50 percent.
- Oncology Momentum: Oncology sales grew 42 percent, supported by new product launches such as Blenrep, which has begun commercial rollout outside the US.
- Vaccines Growth Dynamics: Meningitis vaccines grew 22 percent, and Shingrix expanded 6 percent globally, with ex-US markets driving the majority of growth.
Cash flow generation remained strong, with £3.7 billion generated in the first half of 2025, supporting investment in R&D, business development, and shareholder returns, including a £2 billion share buyback program progressing well.
Executive Commentary
"GSK’s strong momentum in 2025 continues with another quarter of excellent performance driven mainly by Specialty Medicines, our largest business, with double-digit sales growth in Respiratory, Immunology & Inflammation, Oncology and HIV. We also continue to make very good progress in R&D, with 3 major FDA approvals achieved so far this year, 16 assets now in late-stage development, and 4 more promising medicines to treat cancer, liver disease and HIV expected to enter Phase III and pivotal development by the end of the year."
Emma Walmsley, Chief Executive Officer
"Core operating profit grew 12%, with strong leverage in the quarter delivered through a 1% reduction in SG&A, demonstrating our disciplined returns-based approach, and a 70% increase in royalties due to the upfront receipt from the IP settlement announced in April. Core EPS grew 15%, continuing to demonstrate our track record of delivering margin leverage and enhanced by lower interest charges as well as the share buyback."
Julie Brown, Chief Financial Officer
Strategic Positioning
1. Specialty Medicines as Growth Engine
GSK’s strategic focus on specialty medicines is yielding strong returns, with the portfolio delivering 15 percent CER sales growth in Q2. Key assets like Dovato, Cabenuva, and Apretude in HIV, alongside Nucala and Benlysta in RINI, and Jemperli and Ojjaara in oncology, are driving volume and market share gains. The company targets over 50 percent of total sales from specialty by 2031, reflecting a deliberate pivot away from legacy general medicines.
2. R&D Pipeline Expansion and Late-Stage Advances
GSK is investing heavily in R&D, accelerating clinical programs with 66 assets in full clinical development and 16 in late-stage phases. Notable progress includes FDA approvals for Penmenvy meningitis vaccine, Blujepa antibiotic, and Nucala for COPD. The company plans pivotal trials for four new assets in oncology, hepatology, and HIV in H2 2025, emphasizing a pipeline designed to address significant unmet needs and sustain long-term growth.
3. Capital Allocation with Emphasis on Growth and Shareholder Returns
Capital deployment prioritizes growth investments in R&D and business development, exemplified by recent acquisitions like efimosfermin and partnerships such as the collaboration with Hengrui Pharma. Concurrently, GSK maintains disciplined cost management and shareholder returns, progressing a £2 billion share buyback and sustaining dividend payments, balancing reinvestment with capital return.
4. Supply Chain Optimization and US Manufacturing Investment
GSK is actively optimizing its supply chain, including significant investments in US manufacturing capacity to support new modalities and technology platforms. This strategic move aligns with anticipated tariff impacts and regulatory pressures, aiming to enhance operational resilience and cost efficiency over the medium term.
5. Navigating Regulatory and Market Access Challenges
While regulatory processes remain dynamic, particularly with the FDA review extension for Blenrep, GSK maintains constructive dialogue and confidence in approvals. The company is also monitoring US tariff investigations and Medicare Part D redesign impacts, with mitigation strategies in place to manage pricing pressures and market access dynamics.
Key Considerations
GSK’s Q2 results underscore a portfolio in transition, with specialty medicines and vaccines driving growth despite legacy headwinds.
- Product Mix Shift: Continued growth in high-margin specialty medicines enhances gross margin potential despite supply chain and tariff-related cost pressures.
- Regulatory Milestones: Multiple upcoming FDA decisions and pivotal trial readouts will be critical to sustaining momentum and validating pipeline investments.
- Commercial Execution: Strong launches and market penetration, especially in HIV and oncology, highlight effective go-to-market strategies.
- Capital Discipline: Balanced approach to R&D investment, business development, and shareholder returns supports sustainable value creation.
- US Market Focus: Increased US manufacturing and portfolio exposure position GSK to navigate evolving regulatory and tariff environments effectively.
Risks
GSK faces risks from regulatory uncertainties, particularly regarding FDA approvals such as Blenrep, and potential delays that could affect near-term revenue. Tariff investigations and Medicare Part D redesign in the US introduce pricing and reimbursement challenges. Supply chain optimization costs and external macroeconomic factors may pressure margins. Competitive dynamics in specialty medicines and vaccines require sustained innovation and execution to maintain growth trajectories.
Forward Outlook
For Q3 2025, GSK expects continued momentum in specialty medicines and vaccines, with operational investments supporting upcoming product launches. The FDA decision on Depemokimab for asthma is anticipated in December 2025, representing a key regulatory milestone.
- Full-year 2025 guidance raised toward the top end of previous ranges: 3 to 5 percent turnover growth, 6 to 8 percent core operating profit growth, and 6 to 8 percent core EPS growth at CER.
Management highlighted accelerating R&D investment ahead of sales growth, ongoing SG&A productivity initiatives, and the inclusion of enacted and indicated tariffs in guidance assumptions.
Takeaways
GSK’s Q2 2025 results reinforce its strategic pivot to specialty medicines as the primary growth driver, supported by a robust pipeline and disciplined execution.
- Specialty Medicines Momentum: Sustained double-digit growth in HIV, RINI, and oncology confirms the portfolio’s strength and market relevance.
- Pipeline Validation and Expansion: Multiple late-stage assets and new pivotal studies reflect a deepening and broadening innovation engine aligned with high unmet medical needs.
- Operational and Financial Discipline: Margin expansion and strong cash flow generation underpin confidence in meeting elevated 2025 guidance and medium-term targets.
Conclusion
GSK’s Q2 2025 performance demonstrates successful execution of its specialty medicines-led growth strategy, with R&D progress and capital discipline positioning the company well for sustained value creation. Despite external challenges, the company’s confidence in its medium and long-term outlook remains strong, supported by a diversified portfolio and a deep pipeline.
Industry Read-Through
GSK’s results illustrate broader pharmaceutical industry trends emphasizing specialty medicines and biologics as key growth drivers amid pricing and regulatory headwinds. The company’s strategic investments in long-acting injectables and immuno-oncology reflect sector-wide shifts toward innovative, patient-centric therapies. Supply chain resilience and US manufacturing investments underscore the increasing importance of geographic diversification in response to geopolitical risks and tariff uncertainties. Other industry players should monitor GSK’s pipeline progress and regulatory interactions as indicative of evolving market dynamics and competitive positioning.